论文部分内容阅读
我科采用克塞灵(由济世生物工程公司提供)对急性缺血性脑血管病(AICVD)患者治疗的临床研究,旨在对克塞灵治疗AICVD进行评价。 资料和方法 研究对象:以AICVD住院病人为对象,全部病例诊断符合1986年第二次全国脑血管病诊断标准并经CT扫描,除外颅内出血;采用“改良斯堪的纳维亚神经系统功能缺损评分”作为判断标准。
Our department uses ketose (provided by Jishi Bioengineering) for clinical trials of AICVD in patients with acute ischemic cerebrovascular disease (AICVD) and aims to evaluate the efficacy and safety of ketamine in treating AICVD. Materials and Methods Subjects: AICVD inpatients as the object, all cases diagnosed in line with the 1986 national second cerebrovascular disease diagnostic criteria and by CT scan, except for intracranial hemorrhage; using “to improve the Scandinavian nervous system dysfunction Score ”as a criterion.